Oncology Research and Treatment

Published by: S. Karger AG  

People

  1. Motzer
    Motzer
  2. Abou-Alfa
    Abou-Alfa
  3. Mauro
    Mauro
  4. Abida
    Abida
  5. Benayed
    Benayed
  6. Chou
    Chou
  7. Drilon
    Drilon
  8. Hechtman
    Hechtman
  9. Hellmann
    Hellmann
  10. Hsu
    Hsu

Groups

  1. Department of Medicine (20)
  2. Solid Tumor Oncology Division (14)
  3. Genitourinary Oncology Service (7)
  4. Center for Hematologic Malignancies (6)
  5. Hematologic Malignancies, Division of (6)
  6. Gastrointestinal Oncology Service (5)
  7. Adult Leukemia (3)
  8. Bone Marrow Transplant (2)
  9. GSK Faculty (2)
  10. Human Oncology and Pathogenesis Program (2)
Search Within
  1. "2018"
Formats
  1. Meeting Abstract (22)
Groups
  1. Department of Medicine (20)
  2. Solid Tumor Oncology Division (14)
  3. Genitourinary Oncology Service (7)
  4. Center for Hematologic Malignancies (6)
  5. Hematologic Malignancies, Division of (6)
  6. Gastrointestinal Oncology Service (5)

More Groups

People
  1. Robert Motzer (6)
  2. Ghassan Abou-Alfa (4)
  3. Michael Mauro (3)
  4. Alessandro Pastore (1)
  5. Alexander Drilon (1)
  6. Brian Shaffer (1)

More People

Years
  1. 2018 (22)
Publishers
  1. S. Karger AG (22)

Results (22)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Waidmann, O.; Merle, P.; Rimassa, L.; Ryoo, B. Y.; Cicin, I.; Harris, W. P.; Nemunaitis, J.; Olteanu, S.; Sarker, D.; Tan, B. R.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials
    Meeting Abstract

    Haag, G. M.; Chen, L. T.; Kang, Y. K.; Satoh, T.; Kato, K.; Chung, H. C.; Kang, W. K.; Chao, Y.; Chen, J. S.; Ott, P. A.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Venerito, M.; Rimassa, L.; Cicin, I.; Blanc, J. F.; Klümpen, H. J.; Zagonel, V.; Tran, A.; Kim, S.; Lin, Z. Z.; Tam, V. C.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Quantification of drug synergism in vivo exemplified for the combination of Taxotere and T607 against colon carcinoma HCT-116 xenograft tumors in nude mice
    Meeting Abstract

    Ulrich-Merzenich, G.; Fu, J.; Chou, J. H.; Chou, T. C.
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • CheckMate 227: Nivolumab (Nivo) + ipilimumab (Ipi) vs platinum-doublet chemotherapy (Chemo) as first-line treatment for advanced non-small cell lung cancer (NSCLC) with high tumor mutational burden (TMB)
    Meeting Abstract

    Reck, M.; Hellmann, M. D.; Paz-Ares Rodriguez, L.; Ramalingam, S. S.; Brahmer, J.; O'Byrne, K. J.; Bhagavatheeswaran, P.; Nathan, F.; Borghaei, H.
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Venerito, M.; Kelley, R. K.; Ryoo, B. Y.; Merle, P.; Park, J. W.; Bolondi, L.; Chan, S. L.; Lim, H. Y.; Baron, A.; Parnis, F.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial
    Meeting Abstract

    Waidmann, O.; Abou-Alfa, G. K.; Meyer, T.; Cheng, A. L.; El-Khoueiry, A. B.; Rimassa, L.; Ryoo, B. Y.; Cicin, I.; Merle, P.; Chen, Y. H.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Clinicogenetic risk factors in patients receiving autologous stem-cell transplantation after frontline R-CHOP for advanced follicular lymphoma: An analysis from the GLSG2000 trial
    Meeting Abstract

    Alig, S.; Pastore, A.; Jurinovic, V.; Bararia, D.; Häbe, S.; Passerini, V.; Keay, W.; Hellmuth, J.; Rosenwald, A.; Klapper, W.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Ibrutinib/rituximab versus placebo/rituximab in Waldenström's macroglobulinemia (WM): Results of a randomized phase 3 trial
    Meeting Abstract

    Buske, C.; Tedeschi, A.; Trotman, J.; García-Sanz, R.; MacDonald, D.; Leblond, V.; Mahe, B.; Herbaux, C.; Tam, C. S.; Palomba, M. L.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Investigation of HLA loss relapse after allogeneic stem cell transplantation in a global multicentric cohort (HLALOSS Consortium)
    Meeting Abstract

    Fleischhauer, K.; Toffalori, C.; Ahci, M.; Lange, V.; Lang, K.; Todaro, S.; Stempelmann, K.; Heinold, A.; Stölzel, F.; Waterhouse, M.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save

    • Oncology Research and Treatment – authorized name for:

    Name ISSN / ISBN Publisher
    Oncology Research and Treatment 2296-5270 Karger
    Oncology research and treatment 22965262 Unknown
    Oncology Research and Treatment 2296-5270 S. Karger AG
    Oncology Research and Treatment 2296-5270 S. Karger AG